Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmozyme crossover study in chronic airway disease with high sputum NETs
ACTRN12617000395336Phase 4Completed
- Sponsor
- University of Newcastle
- Start
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dornase alfa in chronic obstructive pulmonary disease (COPD), asthma and airway diseases (2 arms), sponsored by University of Newcastle. Primary endpoints: Sputum extracellular DNA level and Detection of neutrophil extracellular traps. Started Jun 2017; status: completed.
02
Drugs
dornase alfa
03
Conditions
chronic obstructive pulmonary disease (COPD)asthmaairway diseases
Beyond the preview
Go deeper on ACTRN12617000395336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000395336.